Mativ (MATV) Q1 2025: $30M Cost Cuts Targeted as Margin Pressures Persist, Portfolio Review Accelerates
Mativ’s first quarter underscored the urgency of its turnaround, as new leadership set aggressive cost and cash flow targets amid persistent demand and margin headwinds. With a comprehensive portfolio review underway and $30–35 million in cost reductions planned by 2026, management is shifting decisively to restore profitability and reduce leverage. The path forward hinges on commercial execution, deeper operational discipline, and the ability to offset structural weaknesses in legacy segments.
Summary
- Turnaround Mandate Intensifies: New CEO pivots to decisive action with portfolio review and deep cost cuts.
- Segment Divergence Widens: SAS momentum contrasts with FAM drag, highlighting portfolio complexity.
- Deleveraging Takes Priority: Free cash flow generation and debt reduction override shareholder returns in near term.
Performance Analysis
MATV’s Q1 results reflected a business at an inflection point: consolidated net sales from continuing operations fell to $485 million, down 3% year-over-year on a reported basis and essentially flat organically. The SAS (Sustainable and Adhesive Solutions) segment delivered its fifth consecutive quarter of EBITDA and margin growth, with organic sales up nearly 6% year-over-year, led by strength in healthcare and release liners (up 20%). In contrast, the FAM (Filtration and Advanced Materials) segment saw sales drop more than 7%, with margin pressure driven by ongoing weakness in automotive and construction end markets, as well as the impact of high-cost inventory and lower volumes.
Adjusted EBITDA fell sharply, down 19% to $37.2 million, as higher manufacturing and distribution costs, unfavorable price/input cost dynamics, and volume declines in FAM outweighed gains in SAS and lower SG&A. Net leverage remains elevated at 4.7x, with management targeting a reduction to 2.5–3.5x by 2026. Cash flow discipline is front and center, with capital expenditures slashed to $40 million for 2025 and inventory reductions of $20–30 million targeted to drive working capital improvements.
- SAS Outperformance: Four straight quarters of sales growth and margin expansion, led by healthcare and release liners.
- FAM Margin Compression: Automotive and construction exposure continue to erode volumes and profitability, with little near-term recovery in sight.
- Cost Structure in Focus: $30–35 million in cost reductions planned by 2026, with $10–15 million realized in 2025 across SG&A, operations, and procurement.
Portfolio complexity and end market exposure remain the core challenge, as management seeks to reallocate resources and accelerate commercial initiatives to offset structural headwinds.
Executive Commentary
"We will not just stand on the sidelines waiting for the demand to come back. We are pivoting to a much higher sense of urgency across our company to act swiftly, comprehensively, and decisively to undertake the necessary changes to grow market share, return to sustainable and profitable growth, and most importantly, restore value to our shareholders."
Shruti Singhal, Chief Executive Officer
"Our number one priority for cash flow utilization is and continues to be deleveraging and debt reduction. With that in mind, as Shruti mentioned, we have major strategic initiatives underway to materially improve cash flow generation throughout 2025."
Greg Weitzel, Chief Financial Officer
Strategic Positioning
1. Commercial Execution Reset
Management is prioritizing enhanced commercial execution, empowering sales teams, aligning incentives to profitable growth, and accelerating cross-selling across SAS and FAM. The new go-to-market strategy, led by Ryan Elbert, has already driven improved outcomes in SAS and is being deployed across the company to unlock new business and market share gains.
2. Aggressive Cost and Cash Discipline
A comprehensive cost review is underway, targeting $30–35 million in reductions by year-end 2026, with $10–15 million realized in 2025. This spans SG&A, operations, and procurement. Capital expenditures are being cut by more than 25% from 2024 levels, and inventory is being right-sized to improve working capital—key levers to accelerate deleveraging and support future investment in growth categories.
3. Portfolio Rationalization and Asset Review
A strategic review of the portfolio is in motion, evaluating each product category’s contribution to margin, competitive positioning, and diversity. The goal is to unlock value, strengthen the balance sheet, and rebalance exposure away from structurally challenged end markets. Early signals point to further divestitures or repositioning as management seeks to streamline the business for sustainable, profitable growth.
4. Localized Supply Chain and Tariff Mitigation
MATV’s local-for-local supply chain model insulates the company from most tariff shocks, with less than 7% of sales exposed to tariffs. Management has developed a playbook for pricing, pass-throughs, and alternative sourcing, and is pursuing share gains where competitors are more exposed to cross-border risk.
5. Segment Focus and Leadership Realignment
Leadership changes in FAM are intended to replicate SAS’s commercial discipline, with a new pipeline build and targeted market expansion in optical, medical, and dental films. However, exposure to weak automotive and construction markets remains a drag, and the pace of offsetting growth in adjacent verticals will be a key watchpoint.
Key Considerations
Q1 marks a decisive pivot for MATV, with new leadership pushing for accelerated transformation and operational discipline. Investors should weigh the following:
Key Considerations:
- Segment Divergence Deepens: SAS’s consistent outperformance is masked by FAM’s drag, underscoring the urgency of portfolio rebalancing.
- Cost Reduction Execution: Delivery of $10–15 million in 2025 cost savings is critical to margin recovery and debt reduction.
- Cash Flow Generation: CapEx and inventory cuts are essential to free up cash for deleveraging, with management signaling no buybacks until leverage targets are met.
- Portfolio Review Outcomes: The scope and speed of asset rationalization will determine how quickly MATV can restore margin and competitive focus.
- End Market Exposure: Continued weakness in automotive and construction could overwhelm gains in specialty and healthcare verticals if not addressed swiftly.
Risks
MATV faces elevated execution risk as it juggles a complex turnaround with persistent demand softness and high leverage. Margin recovery is vulnerable to further macro shocks, especially in FAM, and the success of cost and portfolio actions is not assured. Dividend continuity may face scrutiny if deleveraging stalls or cash flow underdelivers, despite management’s current signal to maintain payouts.
Forward Outlook
For Q2, management expects:
- A significant sequential step-up in adjusted EBITDA, mirroring last year’s $20 million improvement, driven by SAS volume and improved cost absorption.
- Positive cash flow generation, supported by working capital release and lower CapEx.
For full-year 2025, management maintains:
- $10–15 million in incremental cost reductions, $40 million CapEx, and $20–30 million inventory reduction.
Management emphasized that market demand remains uncertain, with no return to pre-pandemic levels expected in the near term. Leverage reduction is the overriding priority, with buybacks deferred until targets are met.
- Q2 margin recovery hinges on price/input cost improvement and SAS outperformance.
- Portfolio review and execution of cost actions are the key swing factors for the year.
Takeaways
MATV’s Q1 was a clear statement of intent, with new leadership moving to break from a wait-and-see posture and tackle structural challenges head-on.
- Segment Realignment is Critical: SAS continues to show resilience, but FAM’s drag highlights the need for portfolio action and commercial discipline spillover.
- Balance Sheet Repair is Non-Negotiable: Cash flow and cost targets are aggressive but necessary to restore financial flexibility and strategic optionality.
- Execution Risk Remains High: The pace and impact of cost, portfolio, and commercial initiatives will determine if MATV can deliver on its turnaround narrative.
Conclusion
MATV’s Q1 2025 call marked a shift from passive hope to active transformation, with management setting clear cost, cash, and portfolio priorities. Investors should focus on the cadence of cost takeout, margin recovery, and portfolio moves as the primary signals of turnaround credibility in the quarters ahead.
Industry Read-Through
MATV’s experience is a cautionary tale for specialty materials and industrial suppliers exposed to cyclical end markets. The company’s struggle to offset demand weakness in automotive and construction, despite strong specialty verticals, highlights the risk of portfolio complexity and the need for relentless cost and asset discipline. Peers with diversified segments may face similar pressures to rationalize and focus on high-margin, resilient categories. The local-for-local supply chain model’s resilience to tariffs is a competitive advantage, but margin protection requires more than geographic insulation in a prolonged low-demand environment.